SCHEMBL6502615

SCHEMBL6502615

Cc1cc(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)cnc1C(N)=O

nearest known ligand 0.73

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 20/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499325 0.92 MAPK14 (0.70) MAPK14
SCHEMBL6506828 0.86 MAPK14 (0.77) MAPK14
SCHEMBL6506384 0.85 MAPK14 (0.77) MAPK14
SCHEMBL4376168 0.84 MAPK14 (1.00) MAPK14
SCHEMBL29594506 0.84 MAPK14 (0.86) MAPK14
SCHEMBL4376601 0.84 MAPK14 (0.86) MAPK14
SCHEMBL6503356 0.84 MAPK14 (0.75) MAPK14
SCHEMBL6502175 0.83 MAPK14 (0.73) MAPK14
SCHEMBL29593614 0.83 MAPK14 (1.00) MAPK14
SCHEMBL4382587 0.83 MAPK14 (1.00) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US claimed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO claimed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.